Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13,949 result(s) found for: Drug. Displaying page 431 of 698.
    EudraCT Number: 2007-002553-23 Sponsor Protocol Number: H-00982-3256 Start Date*: 2007-10-10
    Sponsor Name:MEDA Pharma GmbH & Co. KG [...]
    1. MEDA Pharma GmbH & Co. KG
    2. MEDA Pharma GmbH & Co. KG
    3. MEDA Pharma GmbH & Co. KG
    4. MEDA Pharma GmbH & Co. KG
    Full Title: Clinical trial to assess the protective effect of the fixed drug combination of disodium cromoglycate plus reproterol in comparison to the single components and placebo in adults with exercise indu...
    Medical condition: Exercise induced asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015649 Exercise induced asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001439-74 Sponsor Protocol Number: 20062080 Start Date*: 2007-09-04
    Sponsor Name:Amgen Inc
    Full Title: A Phase 2, Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
    Medical condition: Advance Squamous Cell Carcinoma of the Head and Neck
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) HU (Completed) DE (Completed) ES (Completed) IT (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003659-63 Sponsor Protocol Number: BGC20-1259-04 Start Date*: 2009-03-13
    Sponsor Name:BTG International Ltd
    Full Title: A multicentre double-blind, placebo-controlled, randomised, parallel-group study to evaluate the safety and efficacy of BGC20-1259 in patients with mild to moderate probable Alzheimer’s Disease.
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000767-41 Sponsor Protocol Number: AGMT_MALT Start Date*: 2008-04-30
    Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
    Full Title: Phase II Trial of Rituximab Plus 2CdA in Patients with Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
    Medical condition: Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060707 MALT lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001430-27 Sponsor Protocol Number: CLL-5 Start Date*: 2008-08-28
    Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
    Full Title: Fludarabine/Rituximab combined with escalating doses of Lenalidomide followed by Rituximab/Lenalidomide in untreated chronic lymphocytic leukemia (CLL) – a dose-finding study with concomitant evalu...
    Medical condition: Untreated chronic lymphocytic leukaemia (B-CLL)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003946 B-Lymphocytic, CLL (Kiel Classification) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000963-41 Sponsor Protocol Number: 104-06-301 Start Date*: 2008-12-03
    Sponsor Name:CELSION CORPORATION
    Full Title: A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox (Thermally Sensitive Liposomal Doxorubicin) in Combination with Radiofrequency Ablation (R...
    Medical condition: patients with Non-Resectable Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007083-22 Sponsor Protocol Number: 37822681SCH2002, INT-1, 10 FEB 2009 Start Date*: 2008-10-01
    Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of JNJ-37822681 Administered Twice Daily in Subjects With Schiz...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-007337-49 Sponsor Protocol Number: CLCI699A2215 Start Date*: 2009-02-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, randomized, double-blind, placebo controlled, multi-center study to evaluate the effects of LCI699 on cortisol in patients with hypertension.
    Medical condition: hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: View results
    EudraCT Number: 2009-009182-34 Sponsor Protocol Number: DOR/2008 Start Date*: 2009-03-30
    Sponsor Name:ALFRED E. TIEFENBACHER (GMBH & CO. KG)
    Full Title: RANDOMIZED, DOUBLE MASKED; ACTIVE CONTROLLED, CROSSOVER PHASE III EQUIVALENCE STUDY OF DORZOLAMIDE 2 % EYE DROPS SOLUTION IN SUBJECTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
    Medical condition: Open angle glaucoma or ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10030348 Open angle glaucoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-008190-58 Sponsor Protocol Number: TMC310911-TiDP21-C201 Start Date*: 2009-04-03
    Sponsor Name:Tibotec Pharmaceuticals
    Full Title: A Phase IIa, open-label, randomized trial in treatment-naïve HIV-1-infected subjects to determine the antiviral activity of 14 days of monotherapy with 4 different dose regimens of TMC310911 co-adm...
    Medical condition: HIV-1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-007365-23 Sponsor Protocol Number: MOR-002 Start Date*: 2009-03-12
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of BMN 110 in Subjects with Mucopolysaccharidosis IVA (Morquio Syndrome)
    Medical condition: Mucopolysaccharidosis Type IV A
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028095 Mucopolysaccharidosis IV LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005449-43 Sponsor Protocol Number: MORAb-003-003 PR Start Date*: 2009-10-29
    Sponsor Name:Morphotek, Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of MORAb-003 (farletuzumab) in Combination with Paclitaxel Therapy in Subjects with Platinum-Resistant or Refractory ...
    Medical condition: Platinum-Resistant or Refractory Relapsed Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014660-19 Sponsor Protocol Number: RDEA594-203 Start Date*: 2009-12-09
    Sponsor Name:Ardea Biosciences, Inc.
    Full Title: Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Safety, Efficacy and Potential Pharmacokinetic Interaction of RDEA594 and Allopurinol in Gout Patients w...
    Medical condition: Gout
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10018627 Gout PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-005115-17 Sponsor Protocol Number: CS I-020502/02 Start Date*: 2009-09-23
    Sponsor Name:Kuros Biosurgery AG
    Full Title: A phase 2b, multi-centre, randomized, intra-patient-controlled dose-finding study of I-020502 in patients undergoing autologous meshed skin grafting.
    Medical condition: acute wounds / deep partial and full thickness burns
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043418 Thermal burns HLT
    9.1 10006802 Burns second degree LLT
    9.1 10006803 Burns third degree LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011594-33 Sponsor Protocol Number: SMRI-07TGF-1152 Start Date*: 2009-11-02
    Sponsor Name:LWL University Hospital Bochum, Ruhr-University Bochum
    Full Title: A randomized, double-blind, placebo-controlled study of tetrabenazine as adjunctive therapy to risperidone in first-episode schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016248-37 Sponsor Protocol Number: A1481276 Start Date*: 2010-07-15
    Sponsor Name:Pfizer Ltd., Ramsgate Road, Sandwich, Kent. CT13 9NJ UNITED KINGDOM
    Full Title: A SINGLE ARM SINGLE CENTRE STUDY TO INVESTIGATE SAFETY AND EFFICACY OF SILDENAFIL IN NEAR TERM AND TERM NEWBORNS WITH PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN)
    Medical condition: Persistent pulmonary hypertension of the newborn (PPHN)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10053592 Newborn persistent pulmonary hypertension LLT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000451-34 Sponsor Protocol Number: FARM5XWMZ4 Start Date*: 2007-10-01
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI
    Full Title: Therapy of hyperhomocysteinemia in hemodialysis patients:effects of acetylcysteine and folates.
    Medical condition: Hyperhomocysteinemia in hemodialysis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038359 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-008441-38 Sponsor Protocol Number: ISRCTN76912190 Start Date*: 2011-02-17
    Sponsor Name:London School Of Hygiene and Tropical Medicine
    Full Title: Tranexamic acid for the treatment of postpartum haemorrhage: An international randomised, double blind, placebo controlled trial
    Medical condition: Postpartum haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    13.1 10036417 Post-partum haemorrhage LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019085-82 Sponsor Protocol Number: Y-52-52120-146 Start Date*: 2011-02-24
    Sponsor Name:Ipsen Innovation
    Full Title: A PHASE II, DOUBLE BLIND, RANDOMISED, PLACEBO AND ACTIVE COMPARATOR CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF THREE DOSES OF DYSPORT RU (20 U, 50 U AND 75 U) ADMINISTERED AS A SINGLE TR...
    Medical condition: Moderate to severe glabellar lines
    Disease: Version SOC Term Classification Code Term Level
    13.1 10040785 - Skin and subcutaneous tissue disorders 10052609 Glabellar frown lines LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012916-41 Sponsor Protocol Number: CICL670EDE08T Start Date*: 2010-01-12
    Sponsor Name:CROLLL GmbH
    Full Title: The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (NASH) - a prospective open-label phase I/II trial
    Medical condition: To assess the clinical and biological activity of Deferasirox in patients with NASH and increased iron storage / disturbed distribution of iron on liver function and liver histology
    Disease: Version SOC Term Classification Code Term Level
    14.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Aug 06 08:24:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA